{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:55:56Z","timestamp":1790171756105,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.coviro.2026.101568","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T21:15:54Z","timestamp":1783718154000},"page":"101568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The discovery and development of small molecule immune potentiators (SMIPs) as next-generation vaccine adjuvants, the creation of AS37"],"prefix":"10.1016","volume":"77","author":[{"given":"Elvira","family":"Ianni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Stranges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek T","family":"O\u2019Hagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2026.101568_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2012.00406","article-title":"Mechanism of immunopotentiation and safety of aluminum adjuvants","volume":"3","author":"HogenEsch","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2026.101568_bib2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nri2510","article-title":"Towards an understanding of the adjuvant action of aluminium","volume":"9","author":"Marrack","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coviro.2026.101568_bib3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.coviro.2026.101568_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-018-0089-x","article-title":"Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want","volume":"3","author":"HogenEsch","year":"2018","journal-title":"npj Vaccin"},{"key":"10.1016\/j.coviro.2026.101568_bib5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1136\/bmj.1.5645.663","article-title":"Advantages of aluminium hydroxide adsorbed combined diphtheria, tetanus, and pertussis vaccines for the immunization of infants","volume":"1","author":"Butler","year":"1969","journal-title":"Br Med J"},{"key":"10.1016\/j.coviro.2026.101568_bib6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S1473-3099(04)00927-2","article-title":"Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence","volume":"4","author":"Jefferson","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2026.101568_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4049\/immunohorizons.1700063","article-title":"Recent advances in the discovery and delivery of TLR7\/8 agonists as vaccine adjuvants","volume":"2","author":"Dowling","year":"2018","journal-title":"ImmunoHorizons"},{"key":"10.1016\/j.coviro.2026.101568_bib8","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1126\/science.1093616","article-title":"Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA","volume":"303","author":"Diebold","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.coviro.2026.101568_bib9","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1126\/science.1093620","article-title":"Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.coviro.2026.101568_bib10","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1073\/pnas.0400937101","article-title":"Recognition of single-stranded RNA viruses by Toll-like receptor 7","volume":"101","author":"Lund","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2026.101568_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009980","article-title":"Rational design of small molecules as vaccine adjuvants","volume":"6","author":"Wu","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2026.101568_sbref12","article-title":"The scientific journey of a novel adjuvant (AS37) from bench to bedside","volume":"9","author":"D'Oro","year":"2024","journal-title":"npj Vaccin"},{"key":"10.1016\/j.coviro.2026.101568_bib13","doi-asserted-by":"crossref","first-page":"B14","DOI":"10.1016\/j.vaccine.2015.01.088","article-title":"New generation adjuvants - from empiricism to rational design","volume":"33","author":"O'Hagan","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2026.101568_bib14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrmicro1681","article-title":"The perfect mix: recent progress in adjuvant research","volume":"5","author":"Guy","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.coviro.2026.101568_bib15","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, controlled, phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2026.101568_bib16","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(21)02000-6","article-title":"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial","volume":"398","author":"Ella","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2026.101568_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01695-21","article-title":"High-titer neutralizing antibodies against the SARS-CoV-2 Delta variant induced by Alhydroxiquim-II-adjuvanted trimeric spike antigens","volume":"10","author":"Counoupas","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.coviro.2026.101568_bib18","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.coviro.2026.101568_bib19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/erv.11.29","article-title":"Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems","volume":"10","author":"Gar\u00e7on","year":"2011","journal-title":"Expert Rev Vaccin"},{"key":"10.1016\/j.coviro.2026.101568_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.863162","article-title":"Inactivated vaccine Covaxin\/BBV152: a systematic review","volume":"13","author":"Ahmed","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2026.101568_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102298","article-title":"Th1-skewed immune response of whole virion inactivated SARS-CoV-2 vaccine and its safety evaluation","volume":"24","author":"Ganneru","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.coviro.2026.101568_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-021-00327-2","article-title":"Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases","volume":"6","author":"Kumar","year":"2021","journal-title":"npj Vaccin"},{"key":"10.1016\/j.coviro.2026.101568_bib23","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1021\/acs.jmedchem.6b00489","article-title":"Incorporation of phosphonate into benzonaphthyridine Toll-like receptor 7 agonists for adsorption to aluminum hydroxide","volume":"59","author":"Cortez","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2026.101568_bib24","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.xphs.2018.01.024","article-title":"The preparation and physicochemical characterization of aluminum hydroxide\/TLR7a, a novel vaccine adjuvant comprising a small molecule adsorbed to aluminum hydroxide","volume":"107","author":"Malyala","year":"2018","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.coviro.2026.101568_bib25","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jconrel.2016.11.011","article-title":"Adsorption of a synthetic TLR7\/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: a formulation approach","volume":"244","author":"Fox","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.coviro.2026.101568_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-1-60761-585-9_2","article-title":"Preclinical development of AS04","volume":"626","author":"Gar\u00e7on","year":"2010","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.coviro.2026.101568_bib27","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1073\/pnas.1424924112","article-title":"Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus","volume":"112","author":"Bagnoli","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2026.101568_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147767","article-title":"One dose of Staphylococcus aureus 4C-Staph vaccine formulated with a novel TLR7-dependent adjuvant rapidly protects mice through antibodies, effector CD4+ T cells, and IL-17A","volume":"11","author":"Mancini","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2026.101568_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/srep29063","article-title":"Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines","volume":"6","author":"Buonsanti","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2026.101568_bib30","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1016\/j.vaccine.2017.08.009","article-title":"Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model","volume":"35","author":"Misiak","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2026.101568_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-022-00472-2","article-title":"Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice","volume":"7","author":"Grigoryan","year":"2022","journal-title":"npj Vaccin"},{"key":"10.1016\/j.coviro.2026.101568_bib32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41586-021-03530-2","article-title":"Adjuvanting a subunit COVID-19 vaccine to induce protective immunity","volume":"594","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2026.101568_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2094","article-title":"Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake","volume":"9","author":"Liang","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2026.101568_bib34","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/bloodadvances.2017011411","article-title":"Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in nonhuman primates","volume":"1","author":"Francica","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.coviro.2026.101568_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2019.108275","article-title":"Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): a phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugate vaccine","volume":"209","author":"Gonzalez-Lopez","year":"2019","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coviro.2026.101568_sbref36","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.vaccine.2022.12.006","article-title":"Systems analysis of human responses to an aluminium hydroxide-adsorbed TLR7 agonist (AS37) adjuvanted vaccine reveals a dose-dependent and specific activation of the interferon-mediated antiviral response","volume":"41","author":"Siena","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2026.101568_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00641","article-title":"Alum\/Toll-like receptor 7 adjuvant enhances the expansion of the memory B cell compartment within the draining lymph node","volume":"9","author":"Vo","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2026.101568_bib38","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.91020","article-title":"TLR7\/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth","volume":"2","author":"Dowling","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.coviro.2026.101568_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-20346-w","article-title":"Development of a TLR7\/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination","volume":"12","author":"Dowling","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2026.101568_sbref40","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-66878-3","article-title":"Discovery of a small molecule TLR3 agonist adjuvant","volume":"17","author":"Lee","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2026.101568_sbref41","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-025-08582-y","article-title":"Adjuvant activity of a small-molecule TLR4 agonist discovered via structure-based virtual screening","volume":"8","author":"Kadivella","year":"2025","journal-title":"Commun Biol"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187962572600060X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187962572600060X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T21:46:32Z","timestamp":1783719992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187962572600060X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":41,"alternative-id":["S187962572600060X"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2026.101568","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The discovery and development of small molecule immune potentiators (SMIPs) as next-generation vaccine adjuvants, the creation of AS37","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2026.101568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101568"}}